- Home
- AXIL vs BNR Comparison
AXIL vs BNR Comparison
Compare AXIL & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- BNR
- Stock Information
- Founded
- AXIL 2015
- BNR 2014
- Country
- AXIL United States
- BNR China
- Employees
- AXIL N/A
- BNR N/A
- Industry
- AXIL Package Goods/Cosmetics
- BNR Medical Specialities
- Sector
- AXIL Consumer Discretionary
- BNR Health Care
- Exchange
- AXIL Nasdaq
- BNR Nasdaq
- Market Cap
- AXIL 52.6M
- BNR 38.3M
- IPO Year
- AXIL N/A
- BNR 2020
- Fundamental
- Price
- AXIL $8.19
- BNR $6.13
- Analyst Decision
- AXIL
- BNR
- Analyst Count
- AXIL 0
- BNR 0
- Target Price
- AXIL N/A
- BNR N/A
- AVG Volume (30 Days)
- AXIL 18.5K
- BNR 53.5K
- Earning Date
- AXIL 08-14-2025
- BNR 08-21-2025
- Dividend Yield
- AXIL N/A
- BNR N/A
- EPS Growth
- AXIL 93.65
- BNR N/A
- EPS
- AXIL 0.29
- BNR N/A
- Revenue
- AXIL $27,007,463.00
- BNR $72,112,038.00
- Revenue This Year
- AXIL N/A
- BNR $136.32
- Revenue Next Year
- AXIL N/A
- BNR N/A
- P/E Ratio
- AXIL $29.42
- BNR N/A
- Revenue Growth
- AXIL N/A
- BNR 0.53
- 52 Week Low
- AXIL $3.54
- BNR $2.18
- 52 Week High
- AXIL $10.75
- BNR $9.48
- Technical
- Relative Strength Index (RSI)
- AXIL 77.65
- BNR 56.55
- Support Level
- AXIL $6.50
- BNR $6.71
- Resistance Level
- AXIL $8.85
- BNR $9.48
- Average True Range (ATR)
- AXIL 0.75
- BNR 0.85
- MACD
- AXIL 0.29
- BNR 0.17
- Stochastic Oscillator
- AXIL 86.74
- BNR 34.46
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.